Recent medical advances, cardiovascular disorders (CVDs) continue to be major health concerns, and related high mortality. In this context, investigation of the functional biomarkers involved in the development of CVDs to be an active field of study. The study was aimed to evaluate the effect of Biofield Energy Treated/Blessed Proprietary Test Formulation and Biofield Energy Treatment per se on heart biomarkers in L-NAME and high fat diet (HFD)-induced cardiovascular disorders in Sprague Dawley rats. The functional heart biomarkers such as epinephrine, inducible nitric oxide synthase (iNOS), angiotensin-II, C-reactive protein (CRP), cholesterol, troponin-1, and Na+/K+-ATPase were measured using standard ELISA assay. A test formulation was formulated including minerals (magnesium, zinc, copper, calcium, selenium, and iron), vitamins (ascorbic acid, pyridoxine HCl, vitamin B9, cyanocobalamin, and cholecalciferol), Panax ginseng extract, β-carotene, and cannabidiol isolate. In this experiment, nine groups were allocated, in which four were preventive maintenance groups. Each ingredients of the test formulation were divided into two parts; one section was defined as the untreated test formulation, however other part of the test formulation received Biofield Energy Healing/Blessing remotely for about 3 minutes by Mr. Mahendra Kumar Trivedi. Among nine groups, three groups of animals were also received Biofield Energy Healing Treatment per se (at day-15). The results showed that the level of epinephrine was significantly (p≤0.001) reduced by 72.49%, 63.83%, 80.21%, 89.53%, and 84.97% in the G5 (L-NAME + HFD + the Biofield Energy Treated test formulation), G6 (L-NAME + HFD + Biofield Energy Treatment per se to animals from day -15), and G7 (L-NAME + HFD + the Biofield Energy Treated test formulation from day -15), G8 (L-NAME + HFD + Biofield Energy Treatment per se plus the Biofield Energy Treated test formulation from day -15), and G9 (L-NAME + HFD along with Biofield Energy Treatment per se animals plus the untreated test formulation) groups, respectively as compared to the disease control group (G2). The results showed that the level of iNOS was reduced by 15.19%, 15%, and 23.94% in the G5, G8, and G9 groups, respectively as compared to the untreated test formulation group (G4). Moreover, the level of angiotensin-II was decreased by 29.57%, 18.62%, 34.16%, and 33.35% in the G5, G7, G8 and G9 groups, respectively, as compared to the G2 group. The level of CRP was decreased significantly by 17.57%, 44.94% (p≤0.001), and 41.36% (p≤0.001) in the G5, G8, and G9 groups, respectively as compared to the G2 group. Besides, the level of cholesterol was significantly (p≤0.001) decreased by 27.60%, 23.68%, 28.71%, 41.26%, and 36.94% in the G5, G6, G7, G8, and G9 groups, respectively as compared to the G2 group. The level of troponin-1 was decreased significantly (p≤0.05) by 27.53% in the G9 group as compared to the G2 group. The level of Na+/K+-ATPase was significantly increased by 42.16%, 87.87% (p≤0.05), 65.95% (p≤0.05), 31.40%, and 18.48% in the G5, G6, G7, G8, and G9 groups, respectively than G2 group. Overall, the data suggested significance improvement of vital functional heart biomarkers of the Biofield Energy Treated/Blessed test formulation and Biofield Energy Treatment per se along with preventive measure on the animal with respect to various pathological conditions that might be beneficial various types of cardiovascular disorders. Thus, the results showed the significant reduction of cardiovascular disease progression and its complications in the preventive treatment groups (viz. G6, G7, G8, and G9).
